Ozempic's Latest Role: Helping Smokers Quit
Medically reviewed by Drugs.com.
By Ernie Mundell HealthDay Reporter
TUESDAY, July 30, 2024 -- Smokers with diabetes or obesity who take semaglutide (Ozempic/Wegovy) might reap an added benefit: Help in quitting smoking.
A yearlong study found that, compared to people using other diabetes drugs, fewer patients who were taking semaglutide sought out medical help to quit smoking.
That suggests the drug might have already been helping them to quit, researchers noted.
The finding wasn't a complete surprise to researchers at the National Institute on Drug Abuse (NIDA), since "clinical anecdotes that patients treated with semaglutide ... [have] reported reduced desire to smoke" have already been widespread, they said.
The new study was published July 29 in the Annals of Internal Medicine.
How might semaglutide cut down on smoking?
The researchers noted these drugs (along with Mounjaro and Zepbound) are glucagon-like peptide receptor agonists (GLP-1s), which work to suppress appetite by targeting specific receptors in the brain.
Studies in mice have shown that GLP-1s also reduce "nicotine-induced increases in dopamine release" in a specific brain area, "a common mechanism underlying the rewarding effects of addictive drugs," the researchers explained.
The new study was led by NIDA director Dr. Nora Volkow. Her team analyzed data from seven trials, all involving smokers who also had type 2 diabetes.
Almost 223,000 patients were tracked for a year, and they took a variety of diabetes meds, including insulin, metformin and sulfonylureas, among others.
A total of 5,967 of the patients took semaglutide.
Volkow's team looked at the uptake of quit-smoking therapies -- a marker for folks who felt they needed help to quit smoking.
The researchers found that patients taking semaglutide were 32% less likely to seek out such therapies compared to those who took insulin, 24% less likely to do so compared to folks taking sulfonyureas, and 18% less likely compared to folks taking metformin.
Smokers in the study who took semaglutide were only slightly less likely (12%) to need quit-smoking therapies compared to folks who took the other GLP-1 drug tirzepatide (Mounjaro/Zepbound), the team noted.
Volkow's team stressed these results come from a retrospective look at data, and no one is suggesting that doctors start prescribing GLP-1s to help smokers quit at this point in time.
The findings are intriguing, however, and "need to be examined in randomized, clinical trials," the researchers concluded.
This isn't the first time that GLP-1s have appeared to curb addictive behaviors.
Earlier this month, researchers at Case Western Reserve University School of Medicine reported that people taking semaglutide had 50% to 56% decreased odds for either becoming alcoholic or relapsing into alcoholism.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-30 23:15
Read more
- Bird Flu Virus in Canadian Teen Shows Mutations That Could Help It Spread Among Humans
- Micronized Amnion/Chorion Aids Interstitial Cystitis/Bladder Pain Syndrome
- Alcohol-Induced Liver Disease Hospitalizations, Transplants on the Rise
- Orexo initiates new study of OX640 in participants with allergic rhiniti
- Cognitive Therapy, Modafinil, Combo All Beneficial for Multiple Sclerosis Fatigue
- AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions